Omeros (OMER) Debt/Assets Ratio: History & Chart

Omeros Corporation(OMER)

Biotechnology · Seattle, WA

$18.51-0.39 (-2.06%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Omeros Corporation

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.

Seattle, WA

175 employees

www.omeros.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gregory A. Demopulos

View full financials

OMER Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

29.21%

DEBT TO ASSETS RATIO AVG TTM

81.26%

DEBT TO ASSETS RATIO AVG 3Y

86.15%

DEBT TO ASSETS RATIO AVG 5Y

84.71%

DEBT TO ASSETS RATIO AVG 10Y

119.06%

DEBT TO ASSETS RATIO AVG 15Y

109.69%

DEBT TO ASSETS RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-64.06%

CURRENT VS 3Y AVG

-66.10%

CURRENT VS 5Y AVG

-65.52%

CURRENT VS 10Y AVG

-75.47%

CURRENT VS 15Y AVG

-73.37%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.09%

median of 874 covered companies

CURRENT VS SECTOR MEDIAN

+32351.33%

vs the sector median at left

NAME	MARKET CAP	DEBT TO ASSETS RATIO	TTM	3Y	5Y
Omeros Corporation (OMER)	$1.34B	29.21%	81.26%	86.15%	84.71%
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.33B	0.00%	N/A	N/A	N/A
Inhibrx Biosciences Inc. (INBX)vs ›	$1.37B	0.03%	N/A	N/A	N/A
Alpha Tau Medical Ltd (DRTS)vs ›	$1.31B	0.11%	N/A	N/A	N/A
The Pennant Group, Inc. (PNTG)vs ›	$1.39B	0.48%	N/A	N/A	N/A
Braveheart Bio, Inc. (BRVE)vs ›	$1.40B	N/A	N/A	N/A	N/A
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.40B	0.01%	N/A	N/A	N/A
Taysha Gene Therapies, Inc. (TSHA)vs ›	$1.40B	0.12%	N/A	N/A	N/A
AnaptysBio, Inc. (ANAB)vs ›	$1.42B	0.85%	N/A	N/A	N/A
Ultragenyx Pharmaceutical Inc. (RARE)vs ›	$1.42B	0.95%	N/A	N/A	N/A

NAME

MARKET CAP

DEBT TO ASSETS RATIO

TTM

Omeros Corporation (OMER)

$1.34B

29.21%

81.26%

86.15%

84.71%

Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›

$1.33B

0.00%

N/A

Inhibrx Biosciences Inc. (INBX)vs ›

$1.37B

0.03%

N/A

Alpha Tau Medical Ltd (DRTS)vs ›

$1.31B

0.11%

N/A

The Pennant Group, Inc. (PNTG)vs ›

$1.39B

0.48%

N/A

Braveheart Bio, Inc. (BRVE)vs ›

$1.40B

N/A

Kailera Therapeutics, Inc. (KLRA)vs ›

$1.40B

0.01%

N/A

Taysha Gene Therapies, Inc. (TSHA)vs ›

$1.40B

0.12%

N/A

AnaptysBio, Inc. (ANAB)vs ›

$1.42B

0.85%

N/A

Ultragenyx Pharmaceutical Inc. (RARE)vs ›

$1.42B

0.95%

N/A

Debt to Assets Ratio FAQ

What is the debt to assets ratio for Omeros Corporation (OMER)?

The debt to assets ratio for OMER stock is 29.21%.

Is Omeros Corporation's debt to assets ratio high or low?

The debt to assets ratio of 29.21% is 66% below its 5-year average of 84.71%, near the low end of its 5-year range (29.21%–282.27%).

What is the TTM average debt to assets ratio for Omeros Corporation (OMER)?

The TTM average debt to assets ratio for OMER stock is 81.26%.

What is the 3Y average debt to assets ratio for Omeros Corporation (OMER)?

The 3Y average debt to assets ratio for OMER stock is 86.15%.

What is the 5Y average debt to assets ratio for Omeros Corporation (OMER)?

The 5Y average debt to assets ratio for OMER stock is 84.71%.

What is the 10Y average debt to assets ratio for Omeros Corporation (OMER)?

The 10Y average debt to assets ratio for OMER stock is 119.06%.

What is the 15Y average debt to assets ratio for Omeros Corporation (OMER)?

The 15Y average debt to assets ratio for OMER stock is 109.69%.

DATE	DEBT TO ASSETS RATIO
2026-06-30	29.21%
2026-03-31	108.55%
2025-12-31	73.44%
2025-09-30	103.18%
2025-06-30	91.91%
2025-03-31	176.50%
2024-12-31	74.72%
2024-09-30	66.85%
2024-06-30	124.71%
2024-03-31	107.92%
2023-12-31	95.59%
2023-09-30	69.13%
2023-06-30	88.56%
2023-03-31	83.46%
2022-12-31	57.87%
2022-09-30	74.91%
2022-06-30	99.24%
2022-03-31	92.65%
2021-12-31	82.96%
2021-09-30	282.27%
2021-06-30	239.95%
2021-03-31	212.93%
2020-12-31	148.50%
2020-09-30	117.26%
2020-06-30	279.55%
2020-03-31	165.58%
2019-12-31	141.66%
2019-09-30	205.43%
2019-06-30	200.91%
2019-03-31	178.10%
2018-12-31	157.86%
2018-09-30	174.92%
2018-06-30	122.58%
2018-03-31	96.09%
2017-12-31	72.73%
2017-09-30	66.24%
2017-06-30	135.47%
2017-03-31	138.23%
2016-12-31	118.96%
2016-09-30	96.86%
2016-06-30	151.87%
2016-03-31	139.11%
2015-12-31	101.73%
2015-09-30	68.94%
2015-06-30	52.48%
2015-03-31	43.95%
2014-12-31	294.94%
2014-09-30	128.66%
2014-06-30	78.96%
2014-03-31	57.45%
2013-12-31	123.97%
2013-09-30	169.76%
2013-06-30	88.01%
2013-03-31	114.15%
2012-12-31	75.65%
2012-09-30	45.94%
2012-06-30	164.46%
2012-03-31	85.44%
2011-12-31	72.07%
2011-09-30	58.22%
2011-06-30	49.61%
2011-03-31	42.43%
2010-12-31	21.34%
2010-09-30	24.09%
2010-06-30	22.65%
2010-03-31	21.46%
2009-12-31	20.56%
2009-09-30	202.52%
2009-06-30	119.79%
2008-12-31	76.91%

DATE

DEBT TO ASSETS RATIO

2026-06-30

29.21%

2026-03-31

108.55%

2025-12-31

73.44%

2025-09-30

103.18%

2025-06-30

91.91%

2025-03-31

176.50%

2024-12-31

74.72%

2024-09-30

66.85%

2024-06-30

124.71%

2024-03-31

107.92%

2023-12-31

95.59%

2023-09-30

69.13%

2023-06-30

88.56%

2023-03-31

83.46%

2022-12-31

57.87%

2022-09-30

74.91%

2022-06-30

99.24%

2022-03-31

92.65%

2021-12-31

82.96%

2021-09-30

282.27%

2021-06-30

239.95%

2021-03-31

212.93%

2020-12-31

148.50%

2020-09-30

117.26%

2020-06-30

279.55%

2020-03-31

165.58%

2019-12-31

141.66%

2019-09-30

205.43%

2019-06-30

200.91%

2019-03-31

178.10%

2018-12-31

157.86%

2018-09-30

174.92%

2018-06-30

122.58%

2018-03-31

96.09%

2017-12-31

72.73%

2017-09-30

66.24%

2017-06-30

135.47%

2017-03-31

138.23%

2016-12-31

118.96%

2016-09-30

96.86%

2016-06-30

151.87%

2016-03-31

139.11%

2015-12-31

101.73%

2015-09-30

68.94%

2015-06-30

52.48%

2015-03-31

43.95%

2014-12-31

294.94%

2014-09-30

128.66%

2014-06-30

78.96%

2014-03-31

57.45%

2013-12-31

123.97%

2013-09-30

169.76%

2013-06-30

88.01%

2013-03-31

114.15%

2012-12-31

75.65%

2012-09-30

45.94%

2012-06-30

164.46%

2012-03-31

85.44%

2011-12-31

72.07%

2011-09-30

58.22%

2011-06-30

49.61%

2011-03-31

42.43%

2010-12-31

21.34%

2010-09-30

24.09%

2010-06-30

22.65%

2010-03-31

21.46%

2009-12-31

20.56%

2009-09-30

202.52%

2009-06-30

119.79%

2008-12-31

76.91%

Debt to Assets Ratio: 29.21%

OMER Debt to Assets Ratio

OMER Average Debt to Assets Ratio Chart

OMER Current vs Average Debt to Assets Ratio Chart

OMER Debt to Assets Ratio Metrics

OMER Competitors' Debt to Assets Ratio

Leverage Ratios Comparison

Debt to Assets Ratio Formula & Definition

Debt to Assets Ratio FAQ

OMER Debt to Assets Ratio History

Related Metrics